1. SUGT1 controls susceptibility to HIV-1 infection by stabilizing microtubule plus-ends.
- Author
-
Allouch A, Di Primio C, Paoletti A, Lê-Bury G, Subra F, Quercioli V, Nardacci R, David A, Saïdi H, Cereseto A, Ojcius DM, Montagnac G, Niedergang F, Pancino G, Saez-Cirion A, Piacentini M, Gougeon ML, Kroemer G, and Perfettini JL
- Subjects
- Acetylation, Active Transport, Cell Nucleus genetics, Anti-HIV Agents therapeutic use, Cell Cycle Proteins genetics, Drug Resistance, Viral genetics, HIV Infections drug therapy, HIV-1 genetics, Humans, Microtubule-Associated Proteins genetics, Microtubules genetics, Microtubules pathology, Raltegravir Potassium therapeutic use, Virus Replication, Cell Cycle Proteins metabolism, HIV-1 metabolism, Microtubule-Associated Proteins metabolism, Microtubules metabolism
- Abstract
Understanding the viral-host cell interface during HIV-1 infection is a prerequisite for the development of innovative antiviral therapies. Here we show that the suppressor of G2 allele of skp1 (SUGT1) is a permissive factor for human immunodeficiency virus (HIV)-1 infection. Expression of SUGT1 increases in infected cells on human brain sections and in permissive host cells. We found that SUGT1 determines the permissiveness to infection of lymphocytes and macrophages by modulating the nuclear import of the viral genome. More importantly, SUGT1 stabilizes the microtubule plus-ends (+MTs) of host cells (through the modulation of microtubule acetylation and the formation of end-binding protein 1 (EB1) comets). This effect on microtubules favors HIV-1 retrograde trafficking and replication. SUGT1 depletion impairs the replication of HIV-1 patient primary isolates and mutant virus that is resistant to raltegravir antiretroviral agent. Altogether our results identify SUGT1 as a cellular factor involved in the post-entry steps of HIV-1 infection that may be targeted for new therapeutic approaches.
- Published
- 2020
- Full Text
- View/download PDF